Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT

(2021) Xiaowen Zhou et al.   Cell Communication and Signaling

A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses

(2020) Wenjie Zhai et al.   Acta Pharmaceutica Sinica B

A Novel D Peptide Identified by Mirror‐image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy

(2020) Xiuman Zhou et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The CD47-SIRPα Immune Checkpoint

(2020) Meike E.W. Logtenberg et al.   IMMUNITY

Lifting the innate immune barriers to antitumor immunity

(2020) Carla V Rothlin et al.   Journal for ImmunoTherapy of Cancer

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

(2020) Xiuman Zhou et al.   Cell Communication and Signaling

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells

(2020) Demet Candas-Green et al.   Nature Communications

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy

(2020) Hongfei Wang et al.   Journal for ImmunoTherapy of Cancer

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

(2020) Tracy C. Kuo et al.   Journal of Hematology & Oncology

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy

(2019) Beatriz Sanchez-Correa et al.   Cancers

Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma

(2019) Lei Wu et al.   Cancer Immunology Research

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

(2019) Fan Luo et al.   Journal for ImmunoTherapy of Cancer

Harnessing tumor-associated macrophages as aids for cancer immunotherapy

(2019) Xiaolei Li et al.   Molecular Cancer

Tumor intrinsic and extrinsic immune functions of CD155

(2019) Jake. S. O’Donnell et al.   SEMINARS IN CANCER BIOLOGY

CD47-SIRPα Signaling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma

(2019) Shin Pai et al.   Cells

Small Molecules Drive Big Improvements in Immuno-Oncology Therapies

(2018) Bayard R. Huck et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer

(2018) Lifeng Li et al.   CANCER RESEARCH

Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel

(2018) Hiroshi Komoda et al.   Journal of Atherosclerosis and Thrombosis

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

(2018) Qing Zhang et al.   NATURE IMMUNOLOGY

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion

(2018) Xiaojuan Liu et al.   Cell Reports

The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves

(2018) William G. Kerr et al.   JOURNAL OF IMMUNOLOGY

Drug repurposing: progress, challenges and recommendations

(2018) Sudeep Pushpakom et al.   NATURE REVIEWS DRUG DISCOVERY

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural Basis for CD96 Immune Receptor Recognition of Nectin-like Protein-5, CD155

(2018) Felix A. Deuss et al.   STRUCTURE

CD155 knockdown promotes apoptosis via AKT/Bcl-2/Bax in colon cancer cells

(2017) Qianqian Zheng et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses

(2017) Boning Liu et al.   mAbs

Emerging targets in cancer immunotherapy

(2017) Samantha Burugu et al.   SEMINARS IN CANCER BIOLOGY

Poliovirus Receptor: More than a simple viral receptor

(2017) Jonathan R. Bowers et al.   VIRUS RESEARCH

Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds

(2016) Roberto Würth et al.   DRUG DISCOVERY TODAY

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase

(2016) Takashi Inozume et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Polypharmacology: Challenges and Opportunities in Drug Discovery

(2014) Andrew Anighoro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering

(2012) K. F. Stengel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Calcium channel blockers and modulation of innate immunity

(2011) Wenling Liu et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Fragment-Based Drug Design and Drug Repositioning Using Multiple Ligand Simultaneous Docking (MLSD): Identifying Celecoxib and Template Compounds as Novel Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3)

(2011) Huameng Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cytokine Reducing Effect of Azelnidipine in Human Peripheral Blood Mononuclear Cells

(2010) Ryuzea Miura et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Calcium Channel Blockers Differentially Modulate Cytokine Production by Peripheral Blood Mononuclear Cells

(2010) Akira Matsumori et al.   CIRCULATION JOURNAL

Combination use of immune complexes and a Ca2+channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells

(2009) T. Abe et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL